Leiner
This article was originally published in The Tan Sheet
Executive Summary
Gross inventory down $45.4 mil. to $133.9 mil. at second quarter's end compared to prior-year period, reflecting "complexity reduction and supply chain reengineering," company says Nov. 14. Restructuring professional fees and expenses comprised $3.1 mil. of $5.1 mil. in non-recurring expenses for Q2 ended Sept. 30. Sales fell 8% to $151.6 mil. for the quarter, but gross profit as a percentage of sales improved to 21.8% from 21.3% a year ago due to better plant efficiencies, discontinuation of less profitable SKUs. Net loss jumped to $11.9 mil. from $2.6 mil. in prior-year quarter. On Nov. 2, Leiner announced plans to file for Chapter 11 protection in early 2002 (1"The Tan Sheet" Nov. 12, p. 11)...
You may also be interested in...
Leiner Chapter 11 Plan To Include New Capital, Credit, Debt Restructuring
Leiner Health Products will use a tentative $20 mil. equity investment to support ongoing operations as it prepares to seek Chapter 11 protection in early 2002, the company stated
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.